Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PHARMACIST INCENTIVES AND COMPENSATION FOR SERVICES

Executive Summary

PHARMACIST INCENTIVES AND COMPENSATION FOR SERVICES should be part of the drug reimbursement system under Medicaid, the American Society of Hospital Pharmacists (ASHP) maintained in a March 13 letter to HHS Secretary Bowen. "ASHP strongly urges the department to meet the challenge of developing a new, equitable and comprehensive drug reimbursement program which combines incentives for pharmacists to provide the most cost-effective pharmaceutical products with commensurate compensation for services," association Exec VP Joseph Oddis wrote. "To date, efforts to address the need for a new system of pharmacy payment have been unsuccessful," Oddis said. "Efforts to adjust the existing -- and in our view only marginally effective -- MAC program were inartful and only served to perpetuate a system in which product-related costs inappropriately subsidize the cost of professional services. Current proposals simply play with numbers without addressing the issue foursquare," he added. ASHP contended that to establish a new system that is free from "past inequities imposed upon both the government and the profession," the department should set five criteria for its Rx drug reimbursement program: The system should allow for budget limitations, It should "minimize administrative costs to pharmacists and reduce government overhead costs", It should "use marketplace incentives to encourage cost control", Reimbursement should include both product costs and "an incentive to use lower-cost products where possible" and, It should "include payment for professional services."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS009896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel